PE20040687A1 - Quinolinas sustituidas como antagonistas del receptor ccr5 - Google Patents

Quinolinas sustituidas como antagonistas del receptor ccr5

Info

Publication number
PE20040687A1
PE20040687A1 PE2003000648A PE2003000648A PE20040687A1 PE 20040687 A1 PE20040687 A1 PE 20040687A1 PE 2003000648 A PE2003000648 A PE 2003000648A PE 2003000648 A PE2003000648 A PE 2003000648A PE 20040687 A1 PE20040687 A1 PE 20040687A1
Authority
PE
Peru
Prior art keywords
amino
antagonists
ccr5 receptor
azepin
rent
Prior art date
Application number
PE2003000648A
Other languages
English (en)
Inventor
Stefan Jaroch
Laura Dunning
Monica J Kochanny
Wheeseong Lee
Xiongdong Lian
Meina Liang
Shou-Fu Lu
James Onuffer
Gary Phillips
Guo-Ping Wei
Bin Ye
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20040687A1 publication Critical patent/PE20040687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULAS (1a) Y (1b) DONDE R1 ES H, AMINO, ALQUILO, HIDROXI, ENTRE OTROS; R2 Y R3 SON CADA UNO H, ALQUILO, ALQUILO HALOGENADO, ENTRE OTROS; R4 ES H, UNO O MAS GRUPOS ALQUILO; R5 ES H, ARILALQUILO, CICLOALQUILO, ALCOXICARBONILO, ENTRE OTROS; R7* ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS; n ES 0-3; n* ES 1-3. SON COMPUESTOS PREFERIDOS: ACIDO 4-[[[4-(7-CLORO-4-QUINOLINIL)-1-PIPERAZINIL]CARBONIL]AMINO]HEXAHIDRO-1H-AZEPIN-1-CARBOXILICO, 1,1-DIMETILESTER Y ACIDO 4-[[[4-(7-CLORO-4-QUINOLINIL)-1-PIPERAZINIL]CARBONIL]AMINO]HEXAHIDRO-1H-AZEPIN-1-CARBOXILICO METILESTER, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE UNA AFECCION SELECCIONADA ENTRE NEURITIS OPTICA, UVEITIS, APOPLEJIA, ENDOMETROISIS, ENTRE OTROS
PE2003000648A 2002-06-27 2003-06-27 Quinolinas sustituidas como antagonistas del receptor ccr5 PE20040687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45168702P 2002-06-27 2002-06-27

Publications (1)

Publication Number Publication Date
PE20040687A1 true PE20040687A1 (es) 2004-12-01

Family

ID=30001033

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000648A PE20040687A1 (es) 2002-06-27 2003-06-27 Quinolinas sustituidas como antagonistas del receptor ccr5

Country Status (17)

Country Link
US (1) US7220856B2 (es)
EP (1) EP1534681A1 (es)
JP (1) JP2005537247A (es)
CN (1) CN1678586A (es)
AR (1) AR040349A1 (es)
AU (1) AU2003247772A1 (es)
BR (1) BR0312204A (es)
CA (1) CA2489560A1 (es)
IL (1) IL165871A0 (es)
MX (1) MXPA05000081A (es)
NO (1) NO20050429L (es)
PE (1) PE20040687A1 (es)
RU (1) RU2005102004A (es)
TW (1) TW200401774A (es)
UY (1) UY27871A1 (es)
WO (1) WO2004002960A1 (es)
ZA (1) ZA200500790B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
WO2004078744A2 (en) * 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
WO2005018547A2 (en) * 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1882347A (zh) 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
EP1727526A2 (en) * 2004-02-24 2006-12-06 Schering Aktiengesellschaft Piperazine urea derivatives for the treatment of endometriosis
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20070004763A1 (en) * 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
EP1937252B1 (en) 2005-09-19 2017-10-25 Neuronascent, Inc. Compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008142384A1 (en) 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
JPWO2011078369A1 (ja) * 2009-12-25 2013-05-09 持田製薬株式会社 新規アリールウレア誘導体
EA024202B1 (ru) * 2011-06-06 2016-08-31 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Кристаллические полиморфы в, с и d 7-хлор-4-(пиперазин-1-ил)хинолина и способы их получения
RU2609650C2 (ru) 2011-06-19 2017-02-02 Нью-Йорк Юниверсити Способ ингибирования токсичности лейкоцидина ed staphylococcus aureus у субъекта
EP2822936B1 (en) * 2012-03-07 2021-09-08 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
KR20150033652A (ko) 2012-06-20 2015-04-01 노파르티스 아게 보체 경로 조절제 및 그의 용도
NZ708350A (en) * 2012-11-20 2016-08-26 Merial Inc Anthelmintic compounds and compositions and method of using thereof
JP6509747B2 (ja) * 2013-03-04 2019-05-08 ヘルス・サイエンシズ・ノース・リサーチ・インスティチュート キノリンスルホニル誘導体及びそれらの使用
JP6806342B2 (ja) 2015-04-10 2021-01-06 ベイジーン リミテッド インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
MA44007A (fr) * 2016-02-05 2018-12-19 Denali Therapeutics Inc Inhibiteurs du récepteur interagissant avec protéine kinase 1
US10577362B2 (en) 2016-05-04 2020-03-03 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
US10696648B2 (en) * 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3496715B1 (en) * 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
KR20190040990A (ko) 2016-08-26 2019-04-19 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
AU2018301681B2 (en) * 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
CH715452B1 (de) * 2017-08-29 2021-05-14 Chulabhorn Found Derivate und Zusammensetzung von Chinolin und Naphthyridin.
WO2019101188A1 (en) * 2017-11-25 2019-05-31 Beigene, Ltd. Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases
CN111741946B (zh) * 2017-12-29 2022-09-23 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
CN111574442A (zh) * 2017-12-29 2020-08-25 杭州阿诺生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂的制备方法
DK3814347T3 (da) 2018-06-27 2023-08-07 Bristol Myers Squibb Co Naphthyridinonforbindelse, der er nyttige som t-celleaktivatorer
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CN113891880A (zh) * 2019-05-22 2022-01-04 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的酰胺取代的咪唑并化合物
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021105497A1 (en) * 2019-11-29 2021-06-03 University Of Copenhagen Small-molecule nadph oxidase 2 inhibitors
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN112979546B (zh) * 2021-02-25 2023-01-31 中国药科大学 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途
TW202304925A (zh) * 2021-03-26 2023-02-01 美商住友製藥腫瘤公司 （呋喃并嘧啶—４—基）哌𠯤化合物及其用途
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
WO2024017858A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel naphthyl and isoquinoline sulfonamide derivatives
WO2024049718A2 (en) * 2022-08-31 2024-03-07 Immunocure Inc. Quinoline piperazine derivatives, pharmaceutical composition and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR84902E (fr) * 1962-08-30 1965-05-07 Rhone Poulenc Sa Nouveaux dérivés de la quinoléine et leur préparation
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CN1091103C (zh) * 1999-04-02 2002-09-18 中国科学院上海药物研究所 一类喹诺酮类化合物及它的制备和其用途
BRPI0113146B8 (pt) 2000-08-10 2021-05-25 Mitsubishi Pharma Corp "derivados de prolina e composição farmacêutica que os compreende".
MXPA03002325A (es) * 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same

Also Published As

Publication number Publication date
UY27871A1 (es) 2003-12-31
IL165871A0 (en) 2006-01-15
CN1678586A (zh) 2005-10-05
JP2005537247A (ja) 2005-12-08
US7220856B2 (en) 2007-05-22
ZA200500790B (en) 2006-10-25
NO20050429D0 (no) 2005-01-26
MXPA05000081A (es) 2005-04-11
AR040349A1 (es) 2005-03-30
RU2005102004A (ru) 2005-10-20
AU2003247772A1 (en) 2004-01-19
EP1534681A1 (en) 2005-06-01
NO20050429L (no) 2005-03-29
CA2489560A1 (en) 2004-01-08
TW200401774A (en) 2004-02-01
US20040072818A1 (en) 2004-04-15
WO2004002960A1 (en) 2004-01-08
BR0312204A (pt) 2005-04-26

Similar Documents

Publication Publication Date Title
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
BRPI0417605B8 (pt) “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20050729A1 (es) Aminas ciclicas sustituidas por bezamida o piridin-carboxamida como inhibidores de bace-1
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
PE20051047A1 (es) COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE
PE20090621A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20060646A1 (es) Derivados de bencimidazol como moduladores de la actividad de quimioquinas
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20071064A1 (es) Derivados de pirrolonaftiridinonas como antibacterianos
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren

Legal Events

Date Code Title Description
FC Refusal